Lupin Philippines Inc Pharmaceutical Import Profile — Philippines (DGFT 2022–2026)

Name: Lupin Philippines Inc Pharmaceutical Import Records from India — 3 Products, $2.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Lupin Philippines Inc — Pharmaceutical Importer Profile (2026) | 3 Products, $2.2M Trade | TransData Nexus

Lupin Philippines Inc

Pharmaceutical Importer · Philippines · Tuberculosis Medications Focus · $2.2M Total Trade · DGFT Verified

Lupin Philippines Inc is a pharmaceutical importer based in Philippines with a total trade value of $2.2M across 3 products in 2 therapeutic categories. Based on 45 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Lupin Philippines Inc sources from 4 verified Indian suppliers, with Lupin Limited accounting for 80.7% of imports.

Lupin Philippines Inc — Import Portfolio & Supplier Network

Lupin Philippines Inc import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Lupin Philippines Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Lupin Limited	$3.0M	81	80.7%
Ahlcon Parenterals (india) Limited	$525.1K	13	13.9%
Invex Health Private Limited

What Formulations Does Lupin Philippines Inc Import?

Formulation	Value	Ships
Duomax 24x14t alu / alu philippines rifampin and isoniazid	$500.0K	10
Salbutamol & ipratropium bromide	$400.9K	9
Quadmax 12x14t alu / alu philippines rifampin isoniazid pyrazinamide and ethambutol hydrochloride tablets	$200.0K	4
Duomax 24x14t alu / alu philippines rifampin and isoniazid	$150.0K	3
Quadmax 12x14t alu / alu philippines rifampin, isoniazid, pyrazinamide and ethambutol hydrochloride tablets	$150.0K	3
Quadmax 20x4t (philippines)rifampin 150isoniazid 75 pyrazinamide 400 and ethambutol hcl 275 MG tablets USP	$150.0K	3
Quadmax 12x14t alu / alu philippines rifampin isoniazid pyrazinamide and ethambutol hydrochloride tablets	$150.0K	3
Quadmax 12x14t alu / alu philippines	$145.0K	3
Quadmax tablets USP(rifampin	$100.1K	3
Pharma : cimex 500MG tablets	$100.0K	2
Duomax 24x14t alu / alu philippines	$100.0K	2
Elores INJ. 1.5 GM,geftriaxone/sulbactam1.5 GM/vial powder for solution for INJ.bt no:x3hd054a, manufacturing :aug-23	$100.0K	2
Pharma : duomax tablets (philippines) (rifampin 150MG+isoniazid 75MG) - 1box x 20x4	$100.0K	2
Salbutamol & ipratropium bromide respirator solution 2.5ML (multivent) Pack	$74.2K	3
Pharma : duomax tablets (philippines)	$50.0K	1

Lupin Philippines Inc imports 54 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ethambutol	Tuberculosis Medications	$850.0K	17	0.1%	13
2	Pyrazinamide	Tuberculosis Medications	$850.0K	17	0.1%	11
3	Ipratropium	Respiratory	$484.3K	11	0.6%	10

Lupin Philippines Inc imports 3 pharmaceutical products across 2 categories into Philippines totaling $2.2M.

Lupin Philippines Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Lupin Philippines Inc. is a pharmaceutical importer and distributor based in the Philippines, specializing in the registration, importation, marketing, and distribution of pharmaceutical products. Established on December 20, 2010, the company operates as a wholly-owned subsidiary of Nanomi B.V., formerly known as Lupin Holdings B.V., which is registered in the Netherlands. The ultimate parent company is Lupin Limited, an Indian multinational pharmaceutical company listed on the Bombay Stock Exchange.

Headquartered in Makati City, Lupin Philippines Inc. plays a significant role in the Philippine pharmaceutical distribution network. The company is involved in the importation and distribution of various pharmaceutical formulations, including tablets, capsules, syrups, and injections, sourced primarily from India. This strategic positioning enables Lupin Philippines Inc. to contribute to the availability of essential medications in the Philippine market, particularly in therapeutic areas such as tuberculosis and respiratory conditions.

2Distribution Network

Lupin Philippines Inc. maintains a centralized distribution model with its primary operations based in Makati City, Metro Manila. While specific details regarding additional warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic location in Makati facilitates efficient distribution across the Philippines. This centralization allows for streamlined logistics and effective coverage of the Philippine archipelago, ensuring timely delivery of pharmaceutical products to various regions.

3Industry Role

In the Philippine pharmaceutical supply chain, Lupin Philippines Inc. functions as a pharmaceutical importer and distributor. The company imports finished pharmaceutical formulations from India and distributes them within the Philippine market. By focusing on the importation and distribution of specific therapeutic products, Lupin Philippines Inc. serves as a key player in ensuring the availability of essential medications, particularly in the areas of tuberculosis and respiratory treatments.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Lupin Philippines Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Lupin Philippines Inc. exhibits a high degree of supplier concentration, with 80.7% of its total import value sourced from Lupin Limited, an Indian multinational pharmaceutical company. This significant reliance on a single supplier indicates a strategic choice to maintain a consistent and reliable supply chain. The stability of this relationship is further evidenced by the substantial number of shipments—81 in total—suggesting a well-established and dependable partnership. However, this concentration also presents a potential risk; any disruptions at Lupin Limited could impact Lupin Philippines Inc.'s ability to meet market demand. Diversifying the supplier base could mitigate such risks and enhance supply chain resilience.

2Supply Chain Resilience

Lupin Philippines Inc.'s supply chain resilience is closely tied to its primary supplier, Lupin Limited. The company's import portfolio includes a diverse range of 54 unique pharmaceutical formulations, indicating a broad product offering. However, the heavy reliance on a single supplier for the majority of imports suggests potential vulnerabilities. To enhance resilience, it would be prudent for Lupin Philippines Inc. to establish relationships with additional suppliers and ensure that all imported products comply with the Philippines' regulatory standards, including Good Manufacturing Practice (GMP) certifications.

Importing Pharmaceuticals into Philippines — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Philippines

1Regulatory Authority & Framework

The Food and Drug Administration (FDA) of the Philippines is the primary regulatory body overseeing the importation and distribution of pharmaceutical products. The FDA operates under the Department of Health (DOH) and is responsible for ensuring the safety, efficacy, and quality of drugs entering the country. Key legislation governing pharmaceutical imports includes the FDA Act of 2009 (Republic Act No. 9711) and the Food, Drugs, and Devices Act (Republic Act No. 3720). These laws mandate that all pharmaceutical products be registered with the FDA before they can be imported, sold, or distributed in the Philippines. (respicio.ph)

2Import Licensing & GMP

Importers of pharmaceutical products in the Philippines must secure a License to Operate (LTO) from the FDA. This license authorizes the importation and distribution of specific pharmaceutical products. Additionally, imported pharmaceutical products must be registered with the FDA, ensuring they meet the required safety, efficacy, and quality standards. Good Manufacturing Practice (GMP) certification is a critical component of this process, as it verifies that manufacturing facilities adhere to internationally recognized standards. The FDA recognizes GMP certifications from various regulatory bodies, including the European Union (EU), the World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). (respicio.ph)

Lupin Philippines Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Lupin Philippines Inc. focuses on importing pharmaceutical formulations in the therapeutic areas of tuberculosis and respiratory conditions. This strategic focus aligns with the company's parent, Lupin Limited's, global expertise in anti-tuberculosis medications. The decision to import these specific therapeutic products is likely driven by the high demand for effective treatments in these areas within the Philippine market. By concentrating on these therapeutic categories, Lupin Philippines Inc. aims to address critical health needs and establish a strong presence in these segments.

2Sourcing Profile

Lupin Philippines Inc. primarily sources generic pharmaceutical formulations from India, with a significant portion imported from its parent company, Lupin Limited. This sourcing strategy leverages the established manufacturing capabilities and regulatory compliance of Lupin Limited. The focus on finished pharmaceutical formulations, rather than Active Pharmaceutical Ingredients (APIs) or bulk drugs, indicates a preference for ready-to-market products that meet the specific needs of the Philippine market.

3Market Positioning

Seller's Guide — How to Become a Supplier to Lupin Philippines Inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Lupin Philippines Inc., particularly if they can offer products that complement Lupin Limited's offerings or fill existing gaps in Lupin Philippines Inc.'s portfolio. For instance, introducing innovative formulations or addressing unmet needs in other therapeutic areas could present viable opportunities. However, any potential supplier must ensure compliance with the Philippines' regulatory requirements, including obtaining the necessary licenses and certifications, to establish a successful partnership.

2Requirements & Qualifications

Indian exporters seeking to supply Lupin Philippines Inc. and the broader Philippine market must obtain a License to Operate (LTO) from the FDA, authorizing them to import and distribute pharmaceutical products. Additionally, products must be registered with the FDA and comply with Good Manufacturing Practice (GMP) standards recognized by the FDA. This includes certifications from bodies such as the European Union (EU), the World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Ensuring that products meet these standards is crucial for market entry and acceptance. (respicio.ph)

How to Approach

Frequently Asked Questions — Lupin Philippines Inc

What products does Lupin Philippines Inc import from India?

Lupin Philippines Inc imports 3 pharmaceutical products across 2 categories. Top imports: Ethambutol ($850.0K), Pyrazinamide ($850.0K), Ipratropium ($484.3K).

Who supplies pharmaceuticals to Lupin Philippines Inc from India?

Lupin Philippines Inc sources from 4 verified Indian suppliers. The primary supplier is Lupin Limited (80.7% of imports, $3.0M).

What is Lupin Philippines Inc's total pharmaceutical import value?

Lupin Philippines Inc's total pharmaceutical import value from India is $2.2M, based on 45 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Lupin Philippines Inc focus on?

Lupin Philippines Inc imports across 2 categories. The largest: Tuberculosis Medications (77.8%), Respiratory (22.2%).

Get Full Lupin Philippines Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.